GO:0035491 positive regulation of leukotriene production involved in inflammatory response: Inflammatory Lipid Mediator Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035491 describes any process that increases the rate, frequency or extent of leukotriene synthesis or release following a stimulus as part of an inflammatory response.
• Leukotrienes are eicosanoid lipid mediators generated from arachidonic acid, and their overproduction is linked to asthma, allergy, cardiovascular injury and neuroinflammation.
• Key enzymes include ALOX5 (5-lipoxygenase), ALOX5AP (FLAP), LTC4S, and the PLA2 family that liberates arachidonic acid.
• The process is regulated by neuroimmune crosstalk, including substance P and TRPV1 signaling, and by redox-sensitive inflammatory cascades.
• Dysregulated leukotriene production is observed in primary atopic disorders, viral encephalitis, myocardial ischemia-reperfusion injury and granulomatous inflammation.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of genes controlling leukotriene production.
Description
GO:0035491, positive regulation of leukotriene production involved in inflammatory response, is a Gene Ontology biological process term that captures any mechanism increasing the synthesis or release of leukotrienes during inflammation. Leukotrienes are potent lipid mediators derived from arachidonic acid and are central to allergic, asthmatic and neuroinflammatory responses. Understanding this term is essential because leukotriene overproduction contributes to pathology in multiple organ systems, from the lung to the heart and brain. Researchers studying inflammatory diseases need to identify the upstream regulators and enzymatic steps that drive leukotriene production. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, disease links and experimental models relevant to GO:0035491.
positive regulation of leukotriene production involved in inflammatory response At A Glance
| GO ID | GO:0035491 |
|---|---|
| GO term | positive regulation of leukotriene production involved in inflammatory response |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the rate, frequency or extent of leukotriene synthesis or release during inflammation |
| Key enzymes | ALOX5, ALOX5AP, LTC4S, PLA2 family |
| Key mediators | Leukotriene B4 (LTB4), cysteinyl leukotrienes (LTC4, LTD4, LTE4) |
| Regulatory inputs | Substance P, TRPV1 signaling, redox-sensitive cascades |
| Disease relevance | Asthma, atopic disorders, myocardial ischemia-reperfusion injury, viral encephalitis, granulomatous inflammation |
What Is GO:0035491?
According to QuickGO, GO:0035491 is defined as any process that increases the rate, frequency or extent of the synthesis or release of any leukotriene following a stimulus as part of an inflammatory response. In other words, it is the positive regulatory arm of leukotriene production specifically embedded within inflammatory signaling, encompassing enzymatic activation, substrate mobilization and secretory events that elevate leukotriene levels.
Why Is positive regulation of leukotriene production involved in inflammatory response Important in Cell Biology?
GO:0035491 is important because leukotrienes are among the most potent inflammatory lipid mediators, and their positive regulation determines the magnitude and duration of inflammatory responses in diseases such as asthma, allergy and cardiovascular injury. Pharmacological inhibition of 5-lipoxygenase, as with 11-keto-beta-boswellic acid, protects against myocardial ischemia-reperfusion injury by blunting redox and inflammatory cascades, underscoring the therapeutic relevance of this process. In primary atopic disorders, rapid genomic sequencing can identify mutations in genes controlling leukotriene production, enabling precision diagnosis. Neuroimmune crosstalk involving substance P and TRPV1 further highlights how this GO term integrates neural and immune signals in conditions like nanoplastic-induced asthma exacerbation.
• Leukotrienes are key drivers of bronchoconstriction and airway inflammation in asthma and allergic diseases.
• Positive regulation of leukotriene production is implicated in primary atopic disorders, where genomic sequencing aids diagnosis.
• 5-Lipoxygenase inhibition protects against myocardial ischemia-reperfusion injury, linking this process to cardiovascular pathology.
• Substance P upregulates LTB4 in macrophages during granulomatous inflammation, showing neuroimmune control.
• Eicosanoid pathways, including leukotrienes, modulate immune responses to viral encephalitis.
• Redox-sensitive inflammatory cascades regulate leukotriene production, offering antioxidant therapeutic targets.
• Gut-lung axis and microbiota dysbiosis can coordinate PLA2-TRPV1 neuroimmune crosstalk in asthma exacerbation.
• CRISPR-based models allow causal testing of genes within this GO term for drug discovery.
What Happens During positive regulation of leukotriene production involved in inflammatory response?
Initiation by inflammatory stimuli
In simple terms: Inflammation triggers the process.
Inflammatory stimuli, including neuropeptides such as substance P, activate cells to initiate leukotriene production. This step involves receptor-mediated signaling that couples to phospholipase A2 activation, liberating arachidonic acid from membrane phospholipids. The gut-lung axis and microbiota dysbiosis can amplify these signals through PLA2-TRPV1 neuroimmune crosstalk.
Arachidonic acid mobilization
In simple terms: The raw material for leukotrienes is released.
Phospholipase A2 enzymes hydrolyze membrane phospholipids to release arachidonic acid, the substrate for leukotriene synthesis. This step is rate-limiting and is positively regulated by inflammatory mediators and redox-sensitive cascades. The PLA2 family is therefore a key node in GO:0035491.
5-Lipoxygenase activation and LTA4 formation
In simple terms: The first dedicated enzyme converts the raw material.
ALOX5 (5-lipoxygenase) translocates to the nuclear membrane where it interacts with ALOX5AP (FLAP) to convert arachidonic acid to leukotriene A4 (LTA4). This step is positively regulated by calcium flux and phosphorylation, and is inhibited by selective 5-LOX inhibitors such as 11-keto-beta-boswellic acid.
Terminal leukotriene synthesis
In simple terms: Different enzymes make different final leukotrienes.
LTA4 is converted to LTB4 by LTA4H or to LTC4 by LTC4S, which is then exported and processed to LTD4 and LTE4. These cysteinyl leukotrienes are central to allergic and asthmatic responses, while LTB4 is a potent chemoattractant for neutrophils and macrophages.
Release and amplification
In simple terms: The mediators are released and amplify inflammation.
Newly synthesized leukotrienes are released from cells and act on G-protein-coupled receptors to amplify inflammatory responses, including further leukotriene production. This positive feedback loop is a hallmark of GO:0035491 and is targeted by anti-inflammatory drugs such as NSAIDs.
Key Genes Involved in GO:0035491 positive regulation of leukotriene production involved in inflammatory response
The following genes and proteins are experimentally implicated in the positive regulation of leukotriene production during inflammatory responses.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALOX5 | Converts arachidonic acid to LTA4 | Target of 5-LOX inhibitors; knockout models reduce leukotriene production |
| ALOX5AP | FLAP; presents arachidonic acid to ALOX5 | Essential for 5-LOX activity; knockout abolishes leukotriene synthesis |
| LTA4H | Converts LTA4 to LTB4 | Determines LTB4 levels; target for anti-inflammatory drugs |
| LTC4S | Converts LTA4 to LTC4 | Key for cysteinyl leukotriene synthesis in asthma |
| PLA2G4A | Liberates arachidonic acid | Upstream regulator; knockout reduces substrate availability |
| PLA2G2A | Secretory PLA2; amplifies arachidonic acid release | Linked to gut-lung axis and asthma exacerbation |
| TACR1 | Substance P receptor; activates leukotriene production | Neuroimmune crosstalk; knockout blocks substance P-induced LTB4 |
| TRPV1 | Calcium channel; mediates neuroimmune signaling | Involved in nanoplastic-induced asthma exacerbation |
| PTGS2 | COX-2; modulates eicosanoid balance | Cross-talk with leukotriene pathways; NSAID target |
| ALOX15 | 12/15-lipoxygenase; produces other eicosanoids | Modulates inflammatory tone; potential cross-regulation |
| NFKB1 | Transcription factor driving inflammatory genes | Regulates ALOX5 and PLA2 expression |
| MAPK14 | p38 MAPK; regulates ALOX5 phosphorylation | Inhibitor studies reduce leukotriene production |
| SRC | Tyrosine kinase; upstream of PLA2 activation | Modulates inflammatory signaling |
| CysLT1R | Cysteinyl leukotriene receptor 1 | Mediates feedback amplification; target of montelukast |
| BLT1 | LTB4 receptor | Mediates chemotaxis; knockout reduces inflammation |
| IL4 | Cytokine promoting leukotriene synthesis | Th2 inflammation; atopic disorders |
| IL13 | Cytokine amplifying allergic inflammation | Atopic asthma; genomic sequencing targets |
| FCER1A | High-affinity IgE receptor; mast cell activation | Allergic responses; leukotriene release |
How Is positive regulation of leukotriene production involved in inflammatory response Regulated?
The positive regulation of leukotriene production involved in inflammatory response is controlled at multiple levels. Upstream, neuropeptides such as substance P activate TACR1 and TRPV1, leading to calcium influx and PLA2 activation. Redox-sensitive cascades and MAPK signaling modulate ALOX5 phosphorylation and translocation. Transcription factors such as NFKB1 increase expression of ALOX5 and PLA2 genes during inflammation. Negative regulation is exerted by anti-inflammatory cytokines and pharmacological inhibitors like 11-keto-beta-boswellic acid, which suppresses 5-LOX activity. NSAIDs can shift eicosanoid balance, sometimes paradoxically increasing leukotriene production, highlighting the need for pathway-specific targeting.
positive regulation of leukotriene production involved in inflammatory response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALOX5 | Asthma, myocardial ischemia-reperfusion injury | Alox5 knockout mouse; 5-LOX inhibitor treatment |
| ALOX5AP | Atopic asthma, cardiovascular inflammation | Alox5ap knockout; FLAP inhibitor |
| LTC4S | Cysteinyl leukotriene-driven asthma | Ltc4s knockout; montelukast challenge |
| TACR1 | Granulomatous inflammation, neurogenic asthma | Tacr1 knockout; substance P stimulation |
| PLA2G4A | Nanoplastic-induced asthma exacerbation | Pla2g4a knockout; TRPV1 agonist |
Asthma and atopic disorders
Cysteinyl leukotrienes are major mediators of bronchoconstriction and airway inflammation in asthma. Nanoplastic exposure can exacerbate asthma through gut-lung axis microbiota dysbiosis and PLA2-TRPV1 neuroimmune crosstalk, increasing leukotriene production. Primary atopic disorders often involve mutations in genes controlling leukotriene synthesis, and rapid genomic sequencing can identify these cases for precision management.
Cardiovascular injury
Leukotrienes contribute to myocardial ischemia-reperfusion injury by promoting oxidative stress and inflammation. The selective 5-LOX inhibitor 11-keto-beta-boswellic acid protects against this injury in rats by modulating redox and inflammatory cascades, demonstrating that positive regulation of leukotriene production is a therapeutic target in cardiovascular disease.
Neuroinflammation and viral encephalitis
Eicosanoids, including leukotrienes, play distinct roles in the immune response to viral encephalitis. Substance P upregulates LTB4 in macrophages during granulomatous inflammation, linking neuroimmune signaling to leukotriene production in the central nervous system. NSAIDs may modulate these pathways, but their effects on leukotriene production require careful evaluation.
From positive regulation of leukotriene production involved in inflammatory response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ALOX5 reduce leukotriene production? | ALOX5 knockout cell line or mouse |
| Does a point mutation in ALOX5AP alter FLAP function? | ALOX5AP point-mutation knock-in |
| Can a tagged ALOX5 track nuclear membrane translocation? | ALOX5 tagged knock-in |
| Does LTC4S overexpression increase cysteinyl leukotrienes? | LTC4S overexpression cell model |
| Does TACR1 knockout block substance P-induced LTB4? | TACR1 knockout macrophage |
| Does PLA2G4A knockout affect arachidonic acid release? | PLA2G4A knockout epithelial cell |
How to Study the positive regulation of leukotriene production involved in inflammatory response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | Leukotriene species concentrations | Quantify LTB4, LTC4 after knockout |
| 5-LOX activity assay | Enzymatic conversion of arachidonic acid | Validate ALOX5 inhibitors |
| RNA-seq | Transcript levels of leukotriene pathway genes | Identify inflammatory gene signatures |
| qPCR | Expression of ALOX5, LTC4S, PLA2 | Confirm knockout or overexpression |
| Immunofluorescence | ALOX5 nuclear translocation | Assess activation state |
| Calcium imaging | Intracellular calcium flux | TRPV1-mediated neuroimmune crosstalk |
| ELISA | Secreted LTB4 or cysteinyl leukotrienes | High-throughput screening |
| CRISPR library screening | Genes regulating leukotriene production | Identify novel positive regulators |
Lipidomics and mass spectrometry
Quantitative lipidomics using LC-MS/MS measures leukotriene species such as LTB4, LTC4, LTD4 and LTE4 in cell supernatants or tissues. This method is essential for confirming changes in GO:0035491 activity after genetic or pharmacological perturbation.
Enzyme activity assays
5-Lipoxygenase activity can be measured by monitoring the conversion of arachidonic acid to hydroperoxyeicosatetraenoic acids using spectrophotometric or fluorometric assays. These assays are used to validate ALOX5 and ALOX5AP function in knockout or point-mutation models.
Transcriptomics and qPCR
RNA-seq and qPCR quantify expression of ALOX5, ALOX5AP, LTC4S, PLA2 and receptor genes under inflammatory stimulation. This helps identify transcriptional regulation of GO:0035491 in disease models such as asthma or granuloma.
Imaging and translocation assays
Fluorescence microscopy of tagged ALOX5 or ALOX5AP reveals nuclear membrane translocation, a key activation step. Calcium imaging with TRPV1 agonists can link neuroimmune signaling to leukotriene production.
How CRISPR Can Be Used to Study GO:0035491 positive regulation of leukotriene production involved in inflammatory response
Knockout
CRISPR knockout of ALOX5, ALOX5AP, LTC4S or PLA2 genes abolishes or reduces leukotriene production, providing causal evidence for their role in GO:0035491. Knockout models are used to validate drug targets and to study inflammatory disease mechanisms.
Point Mutation
Point mutations in catalytic residues of ALOX5 or in the arachidonic acid binding pocket of ALOX5AP can dissect enzyme function without complete loss of protein. Such models help distinguish catalytic activity from scaffolding functions in leukotriene production.
Knock-in
Tagged knock-in of ALOX5 or LTC4S with fluorescent or affinity tags enables real-time tracking of protein localization and interaction during inflammatory stimulation. Knock-in of disease-associated variants can model atopic disorders.
Overexpression
Overexpression of LTC4S or PLA2G4A increases leukotriene output, mimicking the positive regulation seen in asthma or cardiovascular injury. Overexpression models are useful for screening inhibitors of GO:0035491.
How EDITGENE Supports positive regulation of leukotriene production involved in inflammatory response Research
Researchers studying positive regulation of leukotriene production involved in inflammatory response-related genes often need to determine whether a candidate gene is causally involved in leukotriene synthesis or release. EDITGENE provides CRISPR-based cell models and screening services to accelerate this discovery process, from knockout validation to point-mutation dissection and overexpression studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of leukotriene production involved in inflammatory response research.
Frequently Asked Questions About positive regulation of leukotriene production involved in inflammatory response
What is GO:0035491?
GO:0035491 is a Gene Ontology biological process term defined as any process that increases the rate, frequency or extent of the synthesis or release of any leukotriene following a stimulus as part of an inflammatory response.
What genes are involved in positive regulation of leukotriene production?
Key genes include ALOX5, ALOX5AP, LTA4H, LTC4S, PLA2G4A, PLA2G2A, TACR1, TRPV1, and receptors such as CysLT1R and BLT1.
How are leukotrienes produced during inflammation?
Inflammatory stimuli activate phospholipase A2 to release arachidonic acid, which is converted by 5-lipoxygenase (ALOX5) and FLAP (ALOX5AP) to LTA4, then to LTB4 or cysteinyl leukotrienes by LTA4H or LTC4S.
What diseases are linked to leukotriene overproduction?
Asthma, atopic disorders, myocardial ischemia-reperfusion injury, viral encephalitis and granulomatous inflammation are linked to leukotriene overproduction.
How can CRISPR help study leukotriene production?
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of genes in the leukotriene pathway and identification of novel regulators.
What is the role of substance P in leukotriene production?
Substance P upregulates LTB4 in rat adherent macrophages from granuloma, demonstrating neuroimmune control of leukotriene production.
Can 5-lipoxygenase inhibitors reduce inflammation?
Yes, the selective 5-LOX inhibitor 11-keto-beta-boswellic acid protects against myocardial ischemia-reperfusion injury by modulating redox and inflammatory cascades.
What is the gut-lung axis role in leukotriene production?
Microbiota dysbiosis can coordinate PLA2-TRPV1 neuroimmune crosstalk in nanoplastic-induced asthma exacerbation, increasing leukotriene production.
How do NSAIDs affect leukotriene production?
NSAIDs can shift eicosanoid balance and may paradoxically increase leukotriene production, which is why pathway-specific targeting is important.
What experimental models are used to study GO:0035491?
Knockout mice, point-mutation knock-in cells, overexpression cell lines, and CRISPR library screens are commonly used to study leukotriene production.
Conclusion
GO:0035491, positive regulation of leukotriene production involved in inflammatory response, is a critical biological process that integrates neuroimmune, redox and enzymatic signals to amplify inflammation. Its dysregulation contributes to asthma, atopic disorders, cardiovascular injury and neuroinflammation, making it a high-value target for therapeutic intervention. CRISPR-based models and lipidomics provide powerful tools to dissect the causal genes and mechanisms within this pathway, accelerating the development of precision anti-inflammatory strategies.
References
- 1. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 2. Zeng X et al.. 2026. Gut-lung axis: a novel mechanism involving microbiota dysbiosis-coordinated PLA2-TRPV1 neuroimmune crosstalk in nanoplastic-induced asthma exacerbation.. Environ Int 207:110047 PMID: 41512508
- 3. Chen N et al.. 2002. Distinct roles of eicosanoids in the immune response to viral encephalitis: or why you should take NSAIDS.. Viral Immunol 15(1):133-46 PMID: 11952135
- 5. Elshazly SM et al.. 2013. The selective 5-LOX inhibitor 11-keto-β-boswellic acid protects against myocardial ischemia reperfusion injury in rats: involvement of redox and inflammatory cascades.. Naunyn Schmiedebergs Arch Pharmacol 386(9):823-33 PMID: 23771412
- 6. Castellani ML et al.. 2009. Substance P upregulates LTB4 in rat adherent macrophages from granuloma induced by KMnO4.. Neurotox Res 15(1):49-56 PMID: 19384587
